Pasireotide vs Semax
Overview
Pasireotide is primarily a hormonal peptide, while Semax is used for cognitive enhancement.
This page compares Pasireotide and Semax across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pasireotide | Semax | |
|---|---|---|
| Category | Hormonal | Cognitive Enhancement |
| Regulatory status (US) | FDA approved | Compounding (Rx) — Apr 2026 |
| Typical dosage | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) | 300-600 mcg |
| Frequency | Twice daily (SC formulation) or every 4 weeks (LAR formulation) | daily |
| Reported benefits | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism | Enhanced focus and memory, neuroprotection, improved learning, mood enhancement, stress resilience |
| Reported side effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) | Generally safe. Possible: overstimulation, sleep disturbances if taken late |
Key differences
Primary use. Pasireotide is categorised under Hormonal, while Semax falls under Cognitive Enhancement. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Pasireotide: FDA-approved. Semax: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)). Semax is typically dosed at 300-600 mcg (daily).
Can you stack them?
Some protocols combine peptides, but stacking Pasireotide and Semax has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pasireotide and Semax?
- Pasireotide is primarily a hormonal peptide, while Semax is used for cognitive enhancement. Pasireotide is FDA-approved for one or more indications, whereas Semax is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- What is Semax used for?
- Cognitive enhancement, focus, memory.
- Can you take Pasireotide and Semax together?
- Some users combine peptides within a single protocol, but stacking Pasireotide and Semax has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pasireotide or Semax FDA-approved?
- Pasireotide is FDA-approved for one or more indications. Semax is not FDA-approved; compounding permitted with a prescription (as of April 2026).
Read the full articles
- Pasireotide — full monograph: mechanism, research, dosing & references
- Semax — full monograph: mechanism, research, dosing & references